LMLLF’s flagship platform is PD-001 – a reformulated and patented version of cepharanthine, with lab data demonstrating potential therapies for a number of anti-cancer and anti-viral indications.
LMLLF is also advancing PD-001 for prostate cancer, filing a provisional patent for cepharanthine combined with chemo for prostate cancer.
LMLLF’s clinical research has developed two potential drug formulations, which have have tested well for low toxicity, and show promising potency and efficacy, and expects to initiate FDA clinical trials in coming months.
DeepMarkit , a featured presenter at Wall Street Reporter’s NEXT SUPER STOCK investors conference, is monetizing the nearly trillion dollar market for carbon credits onto the blockchain, with its Mint Carbon.io platform.
March 23 – MKTDF Signes letter of intent with Top Energy USA to form a carbon offset arrangement pursuant to which Top Energy will introduce and onboard carbon credit projects onto the blockchain through MintCarbon.io.
Wall Street Reporter is the leading financial news provider, focused on giving investors direct access to CEOs of promising, publicly-traded companies, and market experts.
Tourists to Walt Disney World will be able to make a secondary trip to the planet Xandar from Marvel’s Guardians of the Galaxy on May 27.
Let’s look at some of the most well-known EV automakers and charging stocks — such as Rivian Automotive legacy auto industry for that matter — has been dealing with a slew of supply chain challenges for over a year.
It acquired DirecTV to bolster its video business, and after nearly two years of legal wrangling, it successfully acquired Time Warner in an $85 billion deal that closed in June 2018.
In this article, we discuss Charlie Munger’s thoughts on China and his 5 favorite stock picks.
The stocks of three struggling electric vehicle are down between 60% and 70% in the last 12 months.
22 PLUG review we wrote that, “Traders who are long PLUG can continue to hold but I would raise stops to $36 from $31.
Starting early in January, all the main indexes fell, in a broad-based sell-off caused, at least in part, by worries over inflation and the Federal Reserve’s decision to start raising interest rates in response.
Momentum has been building in Nio’s business, but the stock itself has been facing headwinds that have held it back.
UiPath went public at $56 last April and surged to an all-time of $85.12 the following month, but it now trades at about $22.
During an otherwise good day for the market, the Canadian marijuana company’s stock fell by 4% on news that a voluntary ban on share trading by top managers has been accepted by a regulator.
What the retail investor needs is a clear signal, some sign writ large and easy-to-read, to point the way forward.
To rectify this, the company will conduct a 20-for-1 stock split which will reduce its share price to $165, making it much easier for investors across the financial spectrum to own it.